Small volume resuscitation with 20% albumin in intensive care: physiological effects : The SWIPE randomised clinical trial.

2018-11

Mårtensson, Johan

Bihari, Shailesh

Bannard-Smith, Jonathan

Glassford, Neil J

Lloyd-Donald, Patryck

Cioccari, Luca

Luethi, Nora

Tanaka, Aiko

Crisman, Marco

Rey de Castro, Nicolas

Ottochian, Marcus

Huang, Agnes

Cronhjort, Maria

Bersten, Andrew D

Prakash, Shivesh

Bailey, Michael

Eastwood, Glenn M

Bellomo, Rinaldo

Albumin

Critical care

Fluid therapy

Resuscitation

Journal Article

0000-0001-8739-7896

0000-0002-1650-8939

10.1007/s00134-018-5253-2

We set out to assess the resuscitation fluid requirements and physiological and clinical responses of intensive care unit (ICU) patients resuscitated with 20% albumin versus 4-5% albumin. We performed a randomised controlled trial in 321 adult patients requiring fluid resuscitation within 48 h of admission to three ICUs in Australia and the UK. The cumulative volume of resuscitation fluid at 48 h (primary outcome) was lower in the 20% albumin group than in the 4-5% albumin group [median difference - 600 ml, 95% confidence interval (CI) - 800 to - 400; P < 0.001]. The 20% albumin group had lower cumulative fluid balance at 48 h (mean difference - 576 ml, 95% CI - 1033 to - 119; P = 0.01). Peak albumin levels were higher but sodium and chloride levels lower in the 20% albumin group. Median (interquartile range) duration of mechanical ventilation was 12.0 h (7.6, 33.1) in the 20% albumin group and 15.3 h (7.7, 58.1) in the 4-5% albumin group (P = 0.13); the proportion of patients commenced on renal replacement therapy after randomization was 3.3% and 4.2% (P = 0.67), respectively, and the proportion discharged alive from ICU was 97.4% and 91.1% (P = 0.02). Resuscitation with 20% albumin decreased resuscitation fluid requirements, minimized positive early fluid balance and was not associated with any evidence of harm compared with 4-5% albumin. These findings support the safety of further exploration of resuscitation with 20% albumin in larger randomised trials. http://www.anzctr.org.au . Identifier ACTRN12615000349549.

link

Intensive Care Medicine 2018; 44(11): 1797-1806.

Intensive Care Medicine